ORXOY Stock Orexo AB (ORXOY, $2.48) was a top quarterly gainer, rising +67.8%

GET DAILY SIGNALS

Get AI intraday signals

ORXOY - Orexo AB

Loading...

Price: $2.475

Daily change: +$0.565 (+29.58%)

Daily volume: 550

3-month price change: +$1 (+67.8%)

Capitalization: $73.6M

Industry: Pharmaceuticals: Generic

ORXOY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on August 15, 2025

ORXOY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 15 cases where ORXOY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 29, 2025. You may want to consider a long position or call options on ORXOY as a result. In of 36 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ORXOY just turned positive on September 05, 2025. Looking at past instances where ORXOY's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ORXOY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.786) is normal, around the industry mean (17.169). P/E Ratio (0.000) is within average values for comparable stocks, (74.138). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.888). ORXOY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.652) is also within normal values, averaging (46.994).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORXOY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.